James DArecca
Known title: DirectorCIK: 0001583903
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Transaction History
| PBH | ▲ Buy | Grant | 2,981 | $0 | 8/4/2026 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 2,505 | $141K | 5/15/2026 | View on chart |
| HAE | ▲ Buy | Grant | 29,312 | — | 5/15/2026 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 655 | $39K | 5/1/2026 | View on chart |
| PBH | ▲ Buy | Grant | 2,094 | $0 | 8/5/2025 | View on chart |
| HAE | ▲ Buy | Grant | 12,221 | $0 | 5/30/2025 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 5,864 | $407K | 5/30/2025 | View on chart |
| HAE | ▲ Buy | Grant | 7,111 | — | 5/16/2025 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 1,246 | $88K | 5/16/2025 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 622 | $43K | 5/15/2025 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 654 | $42K | 5/2/2025 | View on chart |
| PBH | ▲ Buy | Grant | 2,202 | $0 | 8/6/2024 | View on chart |
| HAE | ▲ Buy | Grant | 4,439 | — | 5/17/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 351 | $33K | 5/16/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 412 | $40K | 5/15/2024 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 432 | $40K | 5/2/2024 | View on chart |
| PBH | ▲ Buy | Grant | 2,295 | $0 | 8/1/2023 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 349 | $31K | 5/16/2023 | View on chart |
| HAE | ▲ Buy | Grant | 4,205 | — | 5/15/2023 | View on chart |
| HAE | ▼ Sell | Tax Withholding | 430 | $35K | 5/2/2023 | View on chart |
| HAE | ▲ Buy | Grant | 4,774 | — | 5/16/2022 | View on chart |
| HAE | ▲ Buy | Grant | 5,902 | — | 5/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Prestige Consumer Healthcare Reports Q1 2027 Earnings
Prestige Consumer Healthcare released the transcript of its Q1 2027 earnings call. The company discussed its quarterly results and outlook, providing detailed guidance on revenue, earnings, and future plans. The release offers investors a clearer view of the company's performance and strategy.
Prestige Consumer Healthcare Reports Q1 2027 Earnings. Prestige Consumer Healthcare released the transcript of its Q1 2027 earnings call. The company discussed its quarterly results and outlook, providing detailed guidance on revenue, earnings, and future plans. The release offers investors a clearer view of the company's performance and strategy.